| P2093 | author name string | Mark E Williams | |
| P2860 | cites work | Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus | Q24244739 |
| | Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group | Q27860882 |
| | The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group | Q27861088 |
| | Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes | Q29547541 |
| | Effects of intensive glucose lowering in type 2 diabetes | Q29547736 |
| | 10-year follow-up of intensive glucose control in type 2 diabetes | Q29615973 |
| | Glucose control and vascular complications in veterans with type 2 diabetes | Q29619213 |
| | A1C variability and the risk of microvascular complications in type 1 diabetes: data from the Diabetes Control and Complications Trial | Q31164826 |
| | Vitamin D and glucose metabolism in chronic kidney disease | Q33899041 |
| | Correlation of glucose regulation and hemoglobin AIc in diabetes mellitus | Q34065358 |
| | Assessing glycemic control in patients with diabetes and end-stage renal failure | Q35075910 |
| | Diabetes control and complications: the role of glycated haemoglobin, 25 years on. | Q35812833 |
| | Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle | Q37175187 |
| | Glycemic control in diabetic CKD patients: where do we stand? | Q37197771 |
| | Frequency of hypoglycemia and its significance in chronic kidney disease. | Q37211078 |
| | Assessing glycemic control in maintenance hemodialysis patients with type 2 diabetes | Q37235928 |
| | Hypoglycemia associated with renal failure. | Q38602967 |
| | Mortality and treatment side-effects during long-term intensified conventional insulin treatment in the Stockholm Diabetes Intervention Study | Q39406012 |
| | Value of serum glycated albumin and high-sensitivity C-reactive protein levels in the prediction of presence of coronary artery disease in patients with type 2 diabetes | Q41938287 |
| | Long-term glycemic control measurements in diabetic patients receiving hemodialysis | Q43882848 |
| | Glucose control in type 2 diabetes: still worthwhile and worth pursuing | Q44153246 |
| | Decreased insulin requirement in relation to GFR in nephropathic Type 1 and insulin-treated Type 2 diabetic patients | Q44520349 |
| | Impact of end-stage renal disease and dialysis on glycemic control | Q44963970 |
| | Hypoglycemia in patients with renal failure | Q45144517 |
| | Class effect of erythropoietin therapy on hemoglobin A(1c) in a patient with diabetes mellitus and chronic kidney disease not undergoing hemodialysis | Q46073594 |
| | Glycated hemoglobin or glycated albumin for assessment of glycemic control in hemodialysis patients with diabetes? | Q46091498 |
| | Glycemic control and survival of diabetic hemodialysis patients--importance of lower hemoglobin A1C levels | Q46168262 |
| | Extremes of glycemic control (HbA1c) increase hospitalization risk in diabetic hemodialysis patients in the USA. | Q46267232 |
| | Glycemic variability: should we and can we prevent it? | Q46786201 |
| | A1C and survival in maintenance hemodialysis patients | Q46840312 |
| | Management of glycemia in patients with diabetes mellitus and CKD. | Q46936954 |
| | Time to move beyond glycosylated haemoglobin | Q47313101 |
| | Insulin action in uremia. | Q54486853 |
| | KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. | Q55043049 |
| | Intravenous calcitriol normalizes insulin sensitivity in uremic patients | Q62775804 |
| | Intractable hypoglycemia in a patient with renal failure | Q67466649 |
| | A pharmacodynamic model of erythropoietin therapy for uremic anemia | Q67732413 |
| | Counterregulatory hormonal response to insulin-induced hypoglycemia in patients on chronic hemodialysis | Q69833370 |
| | Influence of erythropoietin treatment on hemoglobin A1c levels in patients with chronic renal failure on hemodialysis | Q77639712 |
| | Can glycohemoglobin be used to assess glycemic control in patients with chronic renal failure? | Q78014630 |
| | Is there a need to optimize glycemic control in hemodialyzed diabetic patients? | Q79196459 |
| | Glycated albumin is a better glycemic indicator than glycated hemoglobin values in hemodialysis patients with diabetes: effect of anemia and erythropoietin injection | Q79700757 |
| | Hemodialyzed type I and type II diabetic patients in the US: Characteristics, glycemic control, and survival | Q80186543 |
| | Insulin analogue usage in a haemodialysis patient with type 2 diabetes mellitus | Q81344784 |
| | Association of glycated albumin, but not glycated hemoglobin, with peripheral vascular calcification in hemodialysis patients with type 2 diabetes | Q81901680 |
| | Progress in diabetes research--what's next | Q83648597 |
| P433 | issue | 6 | |
| P921 | main subject | renal dialysis | Q202301 |
| P304 | page(s) | 466-472 | |
| P577 | publication date | 2009-12-01 | |
| P1433 | published in | Current diabetes report | Q26841965 |
| P1476 | title | Management of diabetes in dialysis patients | |
| P478 | volume | 9 | |